Areas of Interest

We seek partnering opportunities that address unmet medical needs or could significantly improve the standard of care in the following therapeutic areas:

  • Pain Management
  • Musculoskeletal Disorders
  • Critical Care Medicine

We will pursue partnering opportunities in other therapeutic areas that complement our research and commercial activities.

Pain Management

Asahi Kasei Pharma discovered, developed, and markets the synthetic calcitonin derivative Elcitonin™ (elcatonin) for pain due to osteoporosis.

Our current interests

We are seeking pain management opportunities from preclinical stage to late stage, marketed pharmaceutical products for pain management, as well as research collaborations to develop treatments for pain management.

We are specifically interested in compounds targeting neuropathic pain, osteoarthritis pain, low back pain, fibromyalgia, and cancer pain.

Musculoskeletal Disorders

Asahi Kasei Pharma discovered, developed, and markets the osteoporosis therapeutic agent Teribone™ (teriparatide acetate), the synthetic calcitonin derivative Elcitonin™ (elcatonin) for pain due to osteoporosis, and the immunosuppressant Bredinin™ (mizoribine) for rheumatoid arthritis. Under license, we developed and market the biologic Xiaflex® (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture.

Our current interests

We are seeking opportunities for musculoskeletal disorders, including rheumatoid arthritis, osteoporosis, and osteoarthritis, from preclinical stage to late stage as well as marketed pharmaceutical products for musculoskeletal disorders.

We are also interested in pursuing research collaborations to develop treatments for rheumatoid arthritis.

Critical Care Medicine

Asahi Kasei Pharma discovered, developed, and markets the biologic Recomodulin™ (thrombomodulin alfa) for disseminated intravascular coagulation (DIC).

Our current interests

We are seeking critical care opportunities from preclinical stage to late stage as well as marketed critical care pharmaceutical products, for initial phases of critical care treatment.

Page Top